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Abstract This review gives an overview of the disease
spectrum of congenital diaphragmatic hernia (CDH). Eti-
ological factors, prenatal predictors of survival, new
treatment strategies and long-term morbidity are described.
Early recognition of problems and improvement of treat-
ment strategies in CDH patients may increase survival and
prevent secondary morbidity. Multidisciplinary healthcare
is necessary to improve healthcare for CDH patients.
Absence of international therapy guidelines, lack of evi-
dence of many therapeutic modalities and the relative low
number of CDH patients calls for cooperation between
centers with an expertise in the treatment of CDH patients.
The international CDH Euro-Consortium is an example of
such a collaborative network, which enhances exchange of
knowledge, future research and development of treatment
protocols.
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Abbreviations
CDH Congenital diaphragmatic hernia
ECMO Extra corporeal membrane oxygenation
RA Retinoic acid
LHR Lung-to-head ratio
FLV Fetal lung volume
FETO Fetal tracheal occlusion
BPD Bronchopulmonary dysplasia
HFO High frequency oscillation
VILI Ventilator induced lung injury
iNO Inhaled nitric oxide
PGE1 Prostaglandin
cGMP Cyclic guanosine monophosphate
PDE Phosphodiesterase
cAMP Cyclic adenosine monophosphate
PGI2 Prostacyclin
ET Endothelin
PDGF Platelet-derived growth factor
RSV Respiratory syncytial virus
GER Gastroesophageal reﬂux
Introduction
Congenital diaphragmatic hernia (CDH) is a rare congen-
ital anomaly of the diaphragm with an incidence of
approximately 1 per 2,500 births. Typically, the abdominal
organs will herniate into the chest cavity, with resulting
maldevelopment of the alveoli and pulmonary vessels [1].
The defect is usually, reportedly in 84% of the cases,
located on the left side of the diaphragm. Right-sided CDH
and bilateral CDH, which occur in 14 and 2% of cases, are
associated with a worse prognosis [2]. CDH can present as
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anomalies, such as congenital heart disease or chromo-
somal anomalies [2].
The condition may be life threatening. Mortality rates in
live-born patients range from 10 to 35% [3–6]. The true
mortality may even be higher when taking into account
antenatal death or termination of pregnancy [7]. Key
determinants of mortality are the severity of pulmonary
hypoplasia and the presence of pulmonary hypertension
[1]. Smaller number and generations of airways, thickened
alveolar septa, and abnormal architecture of the respiratory
acinus characterize pulmonary hypoplasia. Pulmonary
hypertension may result from the abnormal pulmonary
vasculature associated with underdevelopment of the
lung [8].
In the earlier days, CDH was regarded as a surgical
emergency and postnatal care was mainly directed towards
early repair of the defect [9]. The 1990s, however, saw
improved survival rates from ‘delayed’ surgical repair, i.e.
after 2 or 3 days’ physiologic stabilization with a ‘gentle’
ventilation strategy, such as permissive hypercapnia [4, 6].
This has now become the initial treatment strategy. The
improved survival rates may also be related to advances
in neonatal care, such as extra corporeal membrane
oxygenation (ECMO) and inhaled nitric oxide (iNO)
[3, 10, 11]. Nevertheless, surviving neonates still carry a
substantial risk of developing secondary morbidity, such
as cardiopulmonary, gastro-intestinal and neurological
problems [12].
Recently, a number of reviews were published either
dealing with speciﬁc center experience or reviewing the
different treatment modalities [2, 13]. Progress in CDH is
hampered by the relative low number in over 80% of
centers (less than ten cases a year); the absence of inter-
national therapy guidelines and the lack of evidence of
many therapeutic modalities. As a consequence, the prob-
lem of CDH can be classiﬁed as ﬁvefold:
• nearly absent knowledge of the etiology,
• variability of phenotype and absence of accepted
parameters of pre- and postnatal prediction of outcome
and targeted intervention,
• absence of properly designed clinical trials with enough
power to determine optimal therapy for respiratory
insufﬁciency and pulmonary hypertension,
• lack of interdisciplinary structured follow-up and a
database to evaluate morbidity throughout childhood
and
• translation of data of animal models of CDH for clinical
practice.
In order to study these problems, the international CDH
Euro-Consortium was started in 2006 to enhance collabo-
ration in these areas of interest.
Etiology
Between the 4th and 12th week of gestation, the diaphragm
arises from the septum transversum, the pleuroperitoneal
folds, the esophageal mesentery, and partly from the tho-
racic body wall. The neuromuscular component of the
diaphragm may be formed by myogenic cells and axons
which coalesce with the pleuroperitoneal folds [14, 15].
Several hypotheses have been suggested in search for an
explanation of the embryologic events that lead to defec-
tive development of the diaphragm. A strong candidate is
mesenchymal malformation of the pleuroperitoneal folds
[14]. Moreover, the ‘dual hit’ hypothesis has suggested that
there is an early insult in lung development before dia-
phragm development, followed by further lung growth
restriction later in gestation [16]. It is still not clear, how-
ever, whether the pulmonary hypoplasia induces or results
from the diaphragmatic defect.
It is also believed that several genetic and environmental
factors may play a role in the development of CDH. One
such environmental factor, as evidenced from animal
models of CDH, is retinoic acid (RA), a derivative from
vitamin A. It has a key role in embryonic development,
including the diaphragm and the lungs [17]. Disturbances
in the RA pathway by gene knock-outs, teratogens or
maternal vitamin A deﬁciency may lead to the develop-
ment of CDH [14, 18, 19]. Furthermore, retinol plasma
concentrations in CDH patients may be lower than those in
healthy newborns [20]. At least, administration of RA at
the end of pregnancy was found to stimulate alveolar
development in rats with CDH [18].
Aneuploidies, genetic syndromes and structural abnor-
malities of chromosomes, such as deletions, duplications,
inversions and translocations, may indicate the involvement
of genetic factors. The most reported aneuploidies in CDH
patients are trisomy 13, 18, 21 and 45X, the most reported
genetic syndrome is Fryns syndrome [21, 22]. The tran-
scription factor COUP-TF2, situated on chromosome
15q26,isoneofthe mostlikelycandidatelociforCDH [23].
Essential for normal limb- and skeletal muscle develop-
ment, COUP-TF2 is instrumental in the RA signaling
pathway and interacts with other CDH candidate genes such
as FOG2 [19, 24]. Mutations in FOG2 cause abnormal
diaphragmatic development and pulmonary hypoplasia
[25]. Thus, both genetic anomalies and disturbances in RA
metabolism may be involved in the development of CDH.
Research questions
• To determine the role of (epi) genetic deletions and
duplications associated with CDH and their inﬂuence
on pathways involved in pulmonary and diaphragm
development.
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possible candidate genes, which may cause abnormal
embryonic development of lungs and diaphragm.
• To investigate the speciﬁc role of the RA-pathway and
the way in which maternal and/or neonatal disturbances
in vitamin A metabolism may inﬂuence the severity of
lung hypoplasia and outcome.
• To study other possible signaling pathways in CDH
lungs, which may be involved in pulmonary and
diaphragm development.
• To identify environmental factors, such as teratogenic
factors,whichmayinﬂuenceprenatallungdevelopment.
Antenatal management
More-detailed ultrasound techniques allow for prenatal
detection of CDH in almost 60% of the cases [26]. Several
prenatal predictors have been proposed to determine post-
natal chances of survival. These predictors may also be
used to determine the need for fetal surgery.
The lung-to-head ratio (LHR), ﬁrst described by Metkus
et al. [29], is the most used prenatal predictor of survival in
fetuses who have CDH [27–30]. It is obtained by dividing
the contralateral lung area to the fetal head circumference
[27]. Good predictive value has been reported for isolated
cases of left-sided CDH, especially when the liver is in
intrathoracic position [29, 31–33]. Others, however, doubt
whether the LHR could predict postnatal outcome [34, 35].
A debatable point is the inter-observer variety that may
occur. Moreover, suitability of the LHR as a predictor of
survival in right-sided CDH has not yet been documented
[36]. Furthermore, LHR may also dependent on the ges-
tational age at measurement and may be less reliable in
mid-gestation [30, 37]. The observed-expected LHR,
which is independent of the timing of assessment, may
therefore be regarded as a better prenatal predictor [38].
Recently, the fetal lung volume (FLV) has been proposed
as a prenatal predictor of survival in fetuses with CDH. The
lower the FLV, the lower the chance of survival and the
highertheneedforECMO[39,40].Itismostlymeasuredby
magnetic resonance imaging (MRI), a reliable method with
good interobserver agreement for measurement of the FLV
[41].Beingdependentonthegestationalageatmeasurement
it is best described as a ratio of the measured volume to the
expected volume [42]. Recently, the observer-to-expected
FLV has been reported to be a better predictor of survival
than the observed-to-expected LHR [43].
Until now, the LHR is usually considered in combination
with the liver’s position to predict postnatal survival. In
isolated cases of CDH, a LHR\1.0 in combination with an
intrathoracic position of the liver is considered unfavorable
and warranting a fetal surgical intervention [27, 28]. The
intervention is a fetal tracheal occlusion (FETO) procedure,
basedontheprinciplethatpluggingofthe trachea,bymeans
of a balloon, will enhance lung growth. Outcomes of FETO
proceduresinCDHpregnancies vary.Somestudiesreported
higher survival rates after a FETO procedure, but others
mentioned complications such as premature rupture of
membranes or premature birth [28].
Prenatal prediction of survival confronts parents and
doctors with difﬁcult decisions on treatment strategies and
possible prenatal interventions. So far, it is not yet clear
which is the most reliable prenatal predictor of survival.
Measurement of the FLV by MRI has shown promising
results. However, the high costs and restricted availability
of MRI systems may limit its clinical application.
Research questions
• To determine sensitive and speciﬁc prenatal predictors
of mortality and morbidity, which may be used to
justify the need for fetal surgical intervention in speciﬁc
cases of CDH.
• To investigate the importance of routine fetal lung
imaging, by either MRI or ultrasound, for predicting
outcome.
Postnatal management
Critical care during the ﬁrst hours of life
Prenatal diagnosis of CDH calls for delivery in a high-
volume center with expertise in the care for newborns with
CDH. A planned delivery, either an induced vaginal
delivery or a caesarean section, is a good option because
most babies with CDH immediately present with cardio-
respiratory stress. Physical examination may reveal a bar-
rel-shaped chest, a scaphoid abdomen, absence of
breathing sounds at the ipsilateral side, shifted cardiac
sounds, and bowel sounds in the chest. A chest X-ray may
show subnormal lung expansion and herniated bowels,
ﬁlled with air or ﬂuid, at the side of the defect. A small
abdominal cavity may be seen, as well as displacement of
the heart and other mediastinal structures to the contralat-
eral side. Liver herniation may appear as a large soft tissue
mass in the thoracic cavity, in which case there is no intra-
abdominal liver shadow.
Immediate intubation is almost always indicated. To
further help lung expansion and decompression of the
abdominal contents, a nasogastric tube with continuous or
intermittent suction and an enema are indicated. Bag
masking may lead to gastro-abdominal distension and
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delivery room consists of conventional mechanical venti-
lation or ventilation by ventilation bag. Peak pressures
should be as low as possible, preferably below 25 cm H2O,
with a FiO2 of 1.0.
Blood pressure support should be given to maintain
arterial blood pressure levels at a normal level for gesta-
tional age. In case of severe right-to-left shunting, higher
blood pressures (meaning above C50 mmHg) have to be
pursued. In case of hypotension and/or poor perfusion,
isotonic ﬂuid therapy (10–20 ml/kg) may be given, pref-
erentially based on cardiac ultrasounds evaluating function
and contractility of the heart. Further blood pressure sup-
port consists of administration of inotropic agents, with
dopamine, epinephrine, norepinephrine, and dobutamine as
primary drugs of choice.
Newborns with CDH will be sedated and anaesthetized.
Depth of sedation has to be evaluated by validated anal-
gesia and sedation scoring systems, such as the COMFORT
Scale [44]. Paralysis should be avoided, as it may have
negative adverse effects on ventilation. However, para-
lyzing medical treatment may be used as a rescue therapy.
Ventilatory support
Pulmonary maldevelopment and asymmetry of the chest
cavity seen in CDH makes ventilation a major challenge.
Prolonged mechanical ventilation and oxygen toxicity may
cause lung damage, which is predisposing to the develop-
ment of chronic lung disease. In children, this is deﬁned as
pulmonary morbidity as a consequence of an acute neo-
natal respiratory disorder, and characterized by abnormal
alveolarization and pulmonary vascular development [45–
48]. Overdistension of the lungs and oxygen toxicity may
be responsible for capillary leakage in the endothelium and
epithelium, rupture of the basement membrane, leakage of
ﬂuid in the alveolar spaces, a general inﬂammatory
response, and impaired surfactant secretion [2]. Moreover,
genetic polymorphisms coding for vascular endothelial
growth factor may be risk factors for developing chronic
lung disease in newborns [49]. The best-known type of
chronic lung disease in infants is bronchopulmonary dys-
plasia (BPD), which occurs mostly in premature and low-
birth weight infants. Despite the fact that they are usually
born at term, one-third of newborns with CDH will develop
BPD versus 20% of preterm infants [46, 50, 51].
Researchers have sought to reduce the risk of ventilator-
induced lung injury (VILI) and subsequent pulmonary
morbidity by means of optimizing ventilation strategies.
Since Wung et al. reported improved survival rates using a
‘gentle’ ventilation strategy, this has become the corner-
stone for ventilation management in newborns with CDH
[6, 52, 53]. ‘Gentle’ ventilation is based on low peak
inspiratory pressures, oxygen saturations of [80%, and
toleration of a rise in CO2 level. This strategy is also called
permissive hypercapnia [2, 53]. Aggressive ventilation
strategies with high peak inspiratory pressures cannot
always be avoided, however, especially in centers without
ECMO facilities.
A new method, high frequency oscillatory ventilation
(HFO), was proposed to increase survival and reduce BPD
in newborns with CDH [53–57]. It effectively achieves
adequate gas exchange by means of an oscillatory pump,
which combines very high respiratory rates with low tidal
volumes. HFO is claimed to reduce the severity of lung
injury induced by mechanical ventilation, by promoting
uniform lung inﬂation, reducing barotrauma, and decreas-
ing the activity of inﬂammatory mediators [53, 58–61]. It is
mostly indicated when hypercarbia persists, refractory to
conventional ventilation. Nevertheless, some centers also
use HFO as an initial ventilation strategy. Observational
and retrospective studies have suggested that HFO is a safe
ventilation strategy in preterm infants as well as in term
neonates [53–56, 61]. However, a Cochrane review found
only a borderline signiﬁcant reduction in the rate of chronic
lung disease in preterm infants with the elective use of
HFO as compared with conventional ventilation [59]. A
second Cochrane review described the use of HFO as a
rescue therapy when conventional ventilation failed in term
and near-term infants with severe pulmonary dysfunction.
Only one trial compared these two ventilation strategies
prospectively, resulting in no signiﬁcant differences in
outcome, need for ECMO, or complications [61, 62]. On
the negative side, HFO may cause lung hyperinﬂation,
which may give rise to higher alveolar and mean airway
pressures in some patients. The adverse effects on venous
return and pulmonary vascular resistance may then
increase the risk of pulmonary barotrauma and hemody-
namic instability [53].
So far, there are only retrospective studies comparing the
use of HFO and conventional ventilation in newborns with
CDH. In one such study the use of HFO prevented hyper-
ventilation as well as the need for ECMO [55].Otherstudies
showed effective CO2 reduction and increased survival in
neonates with CDH and a lower incidence of chronic lung
disease with elective use of HFO. A limitation of these
studies is that they compared different eras and that therapy
protocol was not standardized. Therefore, the results might
have been positively inﬂuenced by other improvements in
neonatal medicine during the last decades [53, 55–57].
Although suggested in many papers, newborns with
CDH have no surfactant deﬁciency [50]. Surfactant inac-
tivation may result either from underdevelopment of the
lungs or from mechanical ventilation and oxygen toxicity
[63–66]. A large retrospective study reported no beneﬁt of
surfactant therapy in newborns with CDH. In fact, survival
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need of ECMO and the incidence of chronic lung disease
were higher [67]. Moreover, surfactant therapy may have
adverse side effects such as severe hypotension. Therefore,
the use of surfactant is not recommended.
Research questions
• To investigate the best primary ventilation mode in
newborns with CDH to prevent VILI and thus
decreasing mortality and pulmonary morbidity.
• To determine underlying (epi) genetic mechanisms,
which may predispose newborns with CDH to develop
chronic lung disease.
• To investigate biomarkers, which may be used to
determine the degree of VILI, lung repair, remodeling
and possible compensatory lung growth.
• To study pre- and postnatal factors, such as immuno-
logic, nutritional and environmental factors, and their
possible interactions with each other, which may
contribute to postnatal lung repair.
Treatment of pulmonary hypertension
As stated before, pulmonary hypertension is a major cause
of mortality in infants with CDH. Severe pulmonary
hypertension usually presents several hours after birth, after
an initial period of relative stability [68]. In healthy neo-
nates, pulmonary vascular resistance decreases after birth as
a result of oxygenation, shear stress and ventilation. This
does not occur in all newborns with CDH, and the pul-
monary vascular walls may remain thickened as a conse-
quence. Pulmonary hypertension is essentially a reversible
process, but may become chronic if treatment should fail.
Chronic pulmonary hypertension is usually unresponsive to
therapy and may lead to right ventricular failure and death.
Apart from the initial morphological changes, the vascular
changes that occur immediately after the neonatal period
are due to hypoxia and hyperoxic exposure of the individual
cells in addition to injury and inﬂammatory mediators. As
such, we consider pulmonary hypertension to be a part of
the disease spectrum in CDH patients and which we propose
to name ‘‘pulmonary vascular disease’’.
Treatment of pulmonary hypertension in infants with
CDH is based on several underlying signaling pathways
involved in the regulation of the vascular tone and the
pathogenesis of pulmonary hypertension [69]. Nitric oxide
(NO) is perhaps the best-known endothelial-derived vaso-
dilator. Inhalation of NO (iNO) interferes with the cGMP
pathway and results in vasodilatation by reducing intra-
cellular calcium levels [70]. In 1992, iNO was introduced
as a treatment for pulmonary hypertension. It may decrease
the pulmonary vascular resistance and right ventricle
afterload, without a decrease in arterial pressure [71].
Several randomized trials with iNO showed improved
oxygenation and a lesser need of ECMO. However, iNO
did not reduce mortality in infants with persistent pul-
monary hypertension [72]. Also, a large RCT demonstrated
no reduction in mortality and need of ECMO in infants
with CDH [73]. As a negative effect, rebound pulmonary
hypertension may occur if iNO is weaned. Although iNO is
used as the golden standard for treating newborns with
pulmonary hypertension, still some 30% of newborns with
CDH do not respond to iNO treatment [74, 75]. However,
although no data are available to show a constant effect in
patients with CDH, so far all trials on iNO are severely
underpowered for CDH. At present, the use of iNO as drug
of choice for the treatment of persistent pulmonary
hypertension is being questioned. Taking into account the
concept of right ventricular workload, more attention is
paid to the ductus of Botalli and potentially restriction of
closure. In a number of studies, PGE1 is advised as ﬁrst
choice. However, no randomized controlled trails are
available to prove its superiority.
Another therapeutic strategy that interferes with the
cGMP pathway is Sildenaﬁl, which is a PDE-5 inhibitor.
Sildenaﬁl may decrease the pulmonary artery pressure
more effectively than does iNO. However, both are equally
effective in decreasing the pulmonary vascular resistance
[76]. Moreover, Sildenaﬁl may increase the efﬁcacy of iNO
and may prevent rebound pulmonary hypertension during
weaning of iNO [77]. In infants with CDH, Sildenaﬁl
improved cardiovascular function and oxygenation in pul-
monary hypertension [78, 79].
Inhibition of PDE-3, which metabolizes cAMP, is
another option for the treatment of pulmonary hyperten-
sion. Milrinone, a PDE-3 inhibitor, was found to decrease
the pulmonary artery pressure and pulmonary resistance in
animals. Milrinone improved oxygenation in neonates with
severe persistent pulmonary hypertension of the newborn
and poor iNO responsiveness [80]. So far, the use of Mil-
rinone has not yet been described in infants with CDH.
Prostacyclin (PGI2) is an endothelial-derived vasodilator
that decreases intracellular calcium levels and thus leads to
vasodilatation [81]. Case reports described the successful
use of prostaglandin treatment in neonates with pulmonary
hypertension [82–84]. De Luca et al. published case reports
on the use of epoprostenol and iloprost, respectively, in the
treatment of pulmonary hypertension in infants with CDH.
For both agents, the child’s clinical condition improved for
several hours [78, 84].
Inhibitors of endothelin (ET), which is a potent vaso-
constrictor produced in the vascular endothelium, may also
improve pulmonary hypertension. In randomized controlled
trials, Bosentan, a non-selective ET receptor antagonist,
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namics in adults with pulmonary hypertension [85, 86]. A
case report described the safe and effective use of bosentan
in two neonates with pulmonary hypertension due to
transposition of the great arteries [87]. Still, liver toxicity
was reported as an important adverse effect of bosentan
[86]. Sitaxsentan and ambrisentan are speciﬁc ET-A
receptor antagonists which may be more effective and less
hepatotoxic than bosentan [88, 89]. No randomized con-
trolled trials have been carried out yet to test the effect of
ET receptor antagonists in neonates.
Platelet-derived growth factors (PDGFs) are upregulated
in pulmonary hypertension [90, 91]. Imatinib, a PDGF
inhibitor, was reported to have a dose-dependent positive
effect on right ventricle hypertrophy and reverse pulmon-
ary vascular remodeling in patients with pulmonary
hypertension [90, 92]. A recent case report described the
use of a tyrosine kinase inhibitor in a newborn with CDH.
It gradually decreased the pulmonary artery pressure and
improved the child’s clinical condition [93].
Finally, the RhoA and Rho-kinase pathways are
involved in maintaining the pulmonary vascular tone and
their downstream effectors form a key pathway for the
regulation of the vascular tone. In animal models, Fasudil,
a Rho-kinase inhibitor, showed promising results in the
treatment of pulmonary hypertension. Fasudil improved
pulmonary hypertension, right ventricle hypertrophy and
also reversed endothelial dysfunction in rats with pul-
monary hypertension [94]. In another study, Fasudil gen-
erated a vasodilatory effect in rats that were unresponsive
to iNO [95].
Research questions
• To investigate mechanisms of pulmonary angiogenesis,
which may explain the postnatal ‘‘maladaption’’ of the
pulmonary circulation in newborns with CDH.
• To investigate the physiology and regulation of the
pulmonary vascular smooth muscle cells.
• To identify new strategies and targets for therapy
including the above-mentioned rho-kinase inhibitors,
PDGF inhibitors, ET receptor antagonists, prostacyclin
and phosphodiesterase inhibitors.
• To determine biomarkers which may be used to
determine the severity of ‘‘pulmonary vascular disease’’.
• To investigate echocardiographic markers to determine
right ventricular function.
Long-term morbidity and multidisciplinary follow-up
Approximately 87% of CDH survivors have longer lasting
associated morbidity, such as pulmonary, gastro-intestinal
and neurological problems. Moreover, they are at risk of
developing surgical problems in later life, such as CDH
recurrence or bowel obstructions because of adhesions.
Associated cardiac or chromosomal anomalies in children
with CDH may involve a wide range of problems, which
may need thorough multidisciplinary follow-up.
Pulmonary morbidity
Approximately 30–50% of CDH survivors develop long-
term pulmonary sequelae, including chronic lung disease,
persistent pulmonary hypertension, asthmatic symptoms,
and recurrent respiratory tract infections [12, 50, 51, 96–
98]. Pulmonary hypoplasia and lung damage due to
mechanical ventilation predisposes newborns with CDH to
develop chronic pulmonary symptoms. Patients who
received ECMO and/or a patch repair are more likely to
develop pulmonary complications [99]. Long-term pul-
monary sequelae may be very diverse, ranging from full
clinical recovery to impaired lung function, respiratory
tract infections, cor pulmonale, and even death. Up to 33%
of CDH patients are oxygen-dependent for a longer time,
compared to 20% of premature and low-birth weight
infants [45, 51, 99].
Forty-three percent of CDH patients are discharged
home with diuretics, and 17% with bronchodilators [99].
Furthermore, during the ﬁrst year of life, approximately
35% required bronchodilator and/or steroid therapy [99].
Half of the CDH survivors show asthma-like symptoms,
such as wheezing and bronchospasm, at one point during
childhood [98]. However, asthma-like symptoms seem to
decline over the years. In 22% of adolscent survivors
asthmatic symptoms have been reported [98].
CDH survivors are also at risk of developing recurrent
pulmonary infections. Pneumonia occurs in 7% of infants
during the ﬁrst year of life [100]. RSV infection, which is
the most common cause of respiratory distress in infants,
may put CDH survivors at a higher risk. RSV vaccination
may therefore be recommended [12]. However, studies
indicated no signiﬁcant differences in respiratory symp-
toms between CDH survivors and controls [50, 98].
Many studies report obstructive lung function abnor-
malities in CDH survivors; restrictive and combined
obstructive/restrictive abnormalities are reported to a lesser
extent [50, 98–103]. Lung function abnormalities occur in
28–52% [99, 100]. Longer duration of ventilation is asso-
ciated with worse pulmonary function [50]. Furthermore,
chest wall deformities, which occur in 46% of the patients,
may be responsible for lung function anomalies [50, 98].
CDH survivors showed higher rates of bronchial hyperre-
activity after provocation tests than controls [50, 98]. It is
hypothesized that this is due to ventilation-induced lung
damage rather than to pulmonary hypoplasia [50]. Apart
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rays are reported in 33–80% of the patients [51, 99]. These
include hyperlucency, hyperinﬂation, persistent lung
hypoplasia, decreased pulmonary vascularity, persistent
lung opacities, mediastinal shift, and abnormal diaphrag-
matic proﬁle [2, 51, 96].
Lung function abnormalities in CDH survivors are rel-
atively mild and usually improve over time, especially after
the ﬁrst 6 months [102]. This may well be due to com-
pensatory growth of the lungs, as V/Q scans show no
reduction in lung volume and a normal diffusion capacity
[50]. CDH patients usually have a good exercise tolerance
and 83% of adult survivors of CDH consider themselves as
healthy [100, 104]. Still, there is much to say for thorough
pulmonary follow-up and lung function tests in CDH sur-
vivors beyond the neonatal period, especially those with
severe chronic lung disease. In milder cases, monitoring of
pulmonary problems is important to assess treatment
strategies. Previous research on lung function abnormali-
ties in CDH survivors was mostly retrospective, and in
small samples. These retrospective data also come from the
era before gentle ventilation strategies and ECMO were
used and are therefore not representative for the present-
day population of patients with CDH. Research should
therefore be directed toward prospective follow-up of lung
function and good monitoring of medication use and pul-
monary problems. New techniques allow us to perform
lung function measurements at a very early age, from
6 months on. Lung function tests early in life are necessary
to start timely treatment that may prevent further damage
from chronic lung disease.
Gastro-intestinal morbidity
Gastroesophageal reﬂux (GER) is a common problem in
CDH survivors. It may be a source of feeding problems,
failure to thrive, esophagitis and respiratory problems if not
treated adequately. Possible explanations of GER in CDH
survivors are esophageal dysmotility, esophageal ectasia,
maldevelopment or weakness of the crura, shortening of
the esophagus, disruption of the angle of His, and a higher
intra-abdominal pressure as a result of the return of the
herniated viscera into the abdomen after surgical repair
[105, 106].
The incidence of GER is 20–84% during the ﬁrst year of
life [107]. An incidence of 63% was reported in adult
survivors of CDH, co-existing with a Barrett’s esophagus
in 54% [108]. Up to 23% of affected infants need such a
surgical correction, such as fundoplication [105, 106]. Risk
factors for a fundoplication in CDH survivors are a patch
repair and an intrathoracal position of the liver [105].
Intestinal obstruction occurs in 4.2–20% of CDH sur-
vivors, compared to 2.2% in other infants who had a
laparotomy. This increased susceptibility may be due to
postoperative transient paralysis of the bowels and intes-
tinal kinking caused by the malrotation [107, 108]. Two-
third of patients who had an intestinal obstruction needed
surgical correction [108].
The high incidence of GER and intestinal obstruction
calls for long-term follow-up of gastro-intestinal problems
in CDH survivors. Moreover, growth impairment is often
reported in CDH survivors, especially in children who
underwent an ECMO-procedure. Adequate treatment of
GER and feeding problems may improve growth impair-
ment [103, 104].
Neurological morbidity
Neurodevelopmental problems are often reported in CDH
survivors [103]. These may be related to hypoxic brain
injury and ECMO treatment. ECMO may be a risk factor
for brain injury as it requires anticoagulant treatment and
ligation of the carotid artery. Furthermore, there is a risk
for hypoxic brain injury before and during ECMO [96]. In
general, neurological sequelae occur in 10–30% of the
children who underwent an ECMO-procedure [109, 110].
Nineteen percent of CDH survivors treated with ECMO
had severe long-term neurodevelopmental problems,
including speech problems and seizure disorders [111].
However, other studies reported ECMO was no risk factor
for poor long-term neurological outcome [112, 113].
Sensoneurinal hearing loss is also reported in CDH
survivors. Ototoxic medication for persistent pulmonary
hypertension has been described as a risk factor for hearing
loss. A recent study reported a 10% incidence of hearing
problems in CDH survivors at the age of 3 years [114].
Motor problems are reported in 60% of CDH survivors
during the ﬁrst year of life and in 73% at the age of
3 years [103, 114]. Duration of ventilation was a predictor
of motor problems at the age of 1 year. Language prob-
lems were detected in 60% of the children at the age of
3 years [114]. Social and behavioral problems were
recorded in approximately 10% of the cases [114]. A study
by Bouman et al. reported a mean IQ of 85 in CDH sur-
vivors, which is one standard deviation below the norm of
100. Also, only half of these children were at the expected
school level [115].
Long-term neurodevelopmental follow-up is important
in CDH survivors. Regular neurological, developmental
and (neuro)psychological assessment by a specialized
pediatrician and a child’s psychologist is recommended. In
case of motor, cognitive, speech and behavorial problems,
further treatment by a physiotherapist, a speech therapist or
a child’s psychologist needs to be considered. Therefore,
neurodevelopmental follow-up is preferably in the hands of
a multidisciplinary team.
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• To determine long-term postnatal pulmonary function
and its course by performing lung function tests and
radio diagnostic imaging in CDH survivors throughout
childhood and into adult life.
• To investigate environmental, nutritional and genetic
risk factors for long-term morbidity in CDH survivors.
• To study social behavior and neuropsychological
development in CDH survivors.
• To determine motor and cognitive development in
CDH survivors.
• To assess quality of life in CDH survivor and their
parents.
Translational approach
Congenital diaphragmatic hernia is a severe congenital
anomaly, which may contribute to signiﬁcant disease bur-
den for both parents and child. Early recognition of prob-
lems and improvement of treatment strategies may increase
survival and prevent secondary morbidity. Therefore,
excellent pre- and postnatal healthcare, standardized
treatment protocols and a well-organized multidisciplinary
follow-up are of high importance in this vulnerable group
of patients. This calls for extensive collaboration between
hospitals, also because of the small number of CDH
patients. The CDH Euro-consortium, which is an interna-
tional collaboration between 16 European high-volume
centers with an expertise in the treatment of children with
CDH, is an example of such a network. The CDH Euro-
Consortium enhances exchange of knowledge, future
research and development of state of the art protocols.
Moreover, this has given rise to a central tissue bank which
facilitates laboratory evaluation of (epi)genetic factors and
speciﬁc biomarkers for chronic lung disease and pulmonary
hypertension. Also, central development of CDH animal
models may be achieved. Knowledge gained from a central
tissue bank and animal models may eventually lead to
improvements in health care [16].
Conclusion
This review aimed to give an overview of the disease
spectrum of CDH. Survival rates have increased because of
the many advances in neonatal care. However, much is still
unknown about the possible etiology, the reliability of
prenatal predictors of survival, ventilation strategies to
reduce VILI, mechanisms of pulmonary hypertension, and
long-term morbidity. Because CDH is a complex disease,
which may have wide-ranging long-term sequelae, multi-
disciplinary healthcare is essential for both parents and
child. Moreover, collaboration between centers, such as the
CDH Euro-Consortium, is highly important for improve-
ments in health care and enhancement of further research.
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